J Rheumatol 2022 Aug 15. Epub 2022 Aug 15.
University of Wisconsin School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, US; University of Wisconsin School of Medicine and Public Health, Department of Medicine, Madison, WI, US; Center for Health Disparities Research, University of Wisconsin School of Medicine and Public Health, Madison, WI, US; University of Wisconsin School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, Madison, WI, US; Division of Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, US; University of Wisconsin - Madison, School of Nursing, Madison, WI, US. Funding sources: Primary source of funding was National Institute on Minority Health and Health Disparities Research (NIMHD) award number R01MD010243. Additional support from NIMHD award number F30MD015211, the University of Wisconsin Medical Scientist Training Program (grant number T32 GM140935), and the University of Wisconsin Clinical and Translational Science Award (NIH CTSA grant 1UL1TR002373). Conflicts of Interests: CMB receives peer-reviewed institutional grant funding from Independent Grants for Learning and Change (Pfizer) for research unrelated to this study. All other authors declare no conflicts. Corresponding author: Christie M Bartels, MD MS, 1685 Highland Ave #4132, Madison, WI 53705. E-mail:
Objective: Recent studies suggest young adults with lupus have high 30-day readmission rates, which may necessitate tailored readmission reduction strategies. To aid in riskstratification for future strategies, we measured 30-day rehospitalization and mortality among Medicare beneficiaries with lupus and determined rehospitalization predictors by age.
Methods: In a 2014 20% national Medicare sample of hospitalizations, rehospitalization risk and mortality within 30 days of discharge were calculated for young (18-35), middle-aged (36-64), and older (65+) beneficiaries with and without lupus. Read More